Cardiac monitoring of high-risk breast cancer patients should be prioritised, after research revealed low rates of heart monitoring seen in the patients receiving trastuzumab.
The post Cardiac monitoring for high-risk breast cancer patients ‘should be prioritised’ appeared first on European Pharmaceutical Review.